Skip to main content
. 2018 Oct 18;4(Suppl 1):e000789. doi: 10.1136/rmdopen-2018-000789

Table 1.

Currently available evidence-based medicine clinical practice guidelines on diagnosis and management of SS

Reference Year Country/organisation Main area of focus Topics covered
Ramos-Casals
et al 11 		2015 EULAR SS task force Characterisation of main organ-specific extraglandular manifestations Articular, cutaneous, pulmonary, renal involvement:

  • Definition of each clinical feature

  • Epidemiological description

  • Key clinical and diagnostic features of each domain.
Brito-Zerón et al 15 2015 EULAR SS task force Early diagnosis of primary SS Diagnostic approach to primary SS suspicion according to the clinical patterns of presentation.
Special focus on organ-specific systemic disease presentations.
Consensus set of recommendations in order to reach an early diagnosis of primary SS.
Foulks et al 16 2015 USA/Sjögren’s Syndrome Foundation Management of dry eye associated with SS Evaluation of dry eye disease in SS: symptom evaluation and diagnostic testing.
Treatment of dry eye disease in SS: algorithm based on severity level and response to therapy.
Zero et al 17 2016 USA/Sjögren’s Syndrome Foundation Management of oral complications of SS Strategies for caries prevention in SS.
Carsons et al 12 2016 USA/Sjögren’s Syndrome Foundation Treatment of rheumatological manifestations of SS Biological therapy for sicca/systemic manifestations.
Treatment and management of fatigue.
csDMARDs for inflammatory musculoskeletal pain.
Valim et al 13 2015 Brazil/Brazilian Society of Rheumatology Treatment of SS General measures and patient education.
Symptomatic management of dryness.
Systemic treatment of glandular and systemic manifestations of SS.
Price et al 14 2017 UK/British Society of Rheumatology Management of dryness and systemic disease in adults with primary SS Management of dryness (ocular, oral, systemic).
Management of fatigue and systemic disease.
Management of pregnancy.
Risk assessment and monitoring of lymphoma.

csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; EULAR, European League Against Rheumatism; SS, Sjögren’s syndrome.